Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (INFARMED)
Record ID 32018001144
English
Authors' objectives:
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. This Joint Assessment aims to compare the clinical effectiveness and safety of siponimod in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.
Details
Project Status:
Completed
URL for project:
https://eunethta.eu/ptja08/
Year Published:
2020
URL for published report:
https://eunethta.eu/ptja08/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Azetidines
- Benzyl Compounds
- Adult
- Sphingosine 1 Phosphate Receptor Modulators
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
Copyright:
CC-BY-NC:
You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.